non inferiority randomized clinical study. Two sided noninferiority test using one-sided of a levle with 95% power assuming an equivalence margin of 0.5 for the IPSS and 0.8 for the peak flow, requiring 300 patients. The sample size was set at 330 (assuming a 10% drop-outs) using one-sided of a level of 0.05 with 95% power. The co-primary endpoints of the study were the changes of IPSS and peak flow after 6 months. The secondary endpoint was the reduction of post-void residual (PVR). One tablet of Profluss1 consisted of 320 mg of supercritical CO2 lipidic extract SeR containing 85% of fatty acids sterols, selenium (50mcg) and lycopene (5mg) and distributed by Konpharma Srl (Rome, Italy). The Treatment-related adverse events (TEAEs) were collected.
non inferiority randomized clinical study. Two sided noninferiority test using one-sided of a levle with 95% power assuming an equivalence margin of 0.5 for the IPSS and 0.8 for the peak flow, requiring 300 patients. The sample size was set at 330 (assuming a 10% drop-outs) using one-sided of a level of 0.05 with 95% power. The co-primary endpoints of the study were the changes of IPSS and peak flow after 6 months. The secondary endpoint was the reduction of post-void residual (PVR) . One tablet of Profluss1 consisted of 320 mg of supercritical CO2 lipidic extract SeR containing 85% of fatty acids sterols, selenium (50mcg) and lycopene (5mg) and distributed by Konpharma Srl (Rome, Italy). The Treatment-related adverse events (TEAEs) were collected.
RESULTS: A total of 303 patients concluded the study protocol, 199 in the group A and 104 in the group B. All patients were balanced at baseline and any statistical difference was found when considering age, IPSS, peak flow, prostate volume, PVR and IIEF-5. After 6 months of therapy we observed a decrease in IPSS of -3 (95%CI -4;-3) and of -3 (95%CI -3;-2) in the group A and B respectively (non inferiority test p¼0.04), an increase in peak flow of 2 (95%CI 2;4) and of 2 (95% 1;3) in the group A and B respectively (non inferiority test p<0.01) and a decrease in PVR of -12 (95%CI -32;-2) and of -10 (95% -25; -5) in the group A and B respectively (non inferiority test p¼0.04). We observed a total of 25 (0.08%) of TEAEs, 5 in the group A (0.02%) and 20 in the group B (0.19%)(p<0.05).
CONCLUSIONS: In this phase IV randomized, non-inferiority clinical trial, we demonstrated that treatment with SeR-Se-Ly was not inferior to Tadalafil 5 mg after 6 months in patients affected by LUTS/BPE and in terms of clinical efficacy and furthermore it showed less TEAEs.
Source of Funding: None

MP09-05 DOES CONCOMITANT TESTOSTERONE REPLACEMENT IMPROVE THE RESPONSE OF TADALAFIL 5 MG ONCE DAILY IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
Hyun Jun Park*, Tae Nam Kim, Jong Kil Nam, Nam Cheol Park, Busan, Korea, Republic of; Du Geon Moon, Seoul, Korea, Republic of INTRODUCTION AND OBJECTIVES: Recently, tadalafil was found to be effective for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Testosterone (T) regulates nitric oxide synthase and is necessary to achieve an optimum response to PDE5 inhibitors. In the present study, we determined whether T replacement in men with low T levels receiving tadalafil to treat LUTS improved the response of tadalafil on LUTS.
METHODS: The present 12-week study was a randomized parallel study of clinical outcomes in men aged 40 years with symptomatic BPH (IPSS 12), prostate volumes 30 ml, and testosterone levels less than 300 ng/dl. Eligible patients received a combination of tadalafil 5 mg once daily and placement of a transdermal gel containing 10 g T (n¼44), or tadalafil alone (n¼46). The primary outcomes were post-treatment IPSS, peak urinary flow rate, and postvoid residual urine volume (PVR). Secondary outcomes were changes in IIEF-EF domain scores, Global Assessment Questionnaire (GAQ) scores, and Life Satisfaction Checklist (LSC) scores.
RESULTS: The extent of IPSS improvement from baseline to 12 weeks was the same in both groups (tadalafil+T -5.2 vs. tadalafil -5.0; p¼0.634). Also, the changes in Q(max) and PVR from baseline were very similar in both groups. However, the tadalafil+T group showed a significantly greater change from baseline in the IPSS storage subscore, the IPSS-QoL score, and the IIEF-EF domain score. The tadalafil+T group showed significantly greater improvements in GAQ and LSC scores, as compared to the tadalafil-only group. The adverse event profiles of each group were similar to those of previous reports.
CONCLUSIONS: Tadalafil plus testosterone was superior to tadalafil alone in improving LUTS in men with BPH/LUTS and low testosterone levels. Further study is needed with more number of patients and longer duration study for support of present study.
Source of Funding: none
MP09-06 ADMINISTRATION OF DAILY 5MG TADALAFIL IMPROVES NOT ONLY LOWER URINARY TRACT SYMPTOMS BUT ALSO VESSEL ENDOTHELIAL FUNCTION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Toshiyasu Amano*, Takahiro Kishikage, Tetsuya Imao, Nagano, Japan INTRODUCTION AND OBJECTIVES: Tadalafil is a promising phosphodiesterase (PDE) 5 inhibitor for erectile dysfunction (ED) treatment. Daily low dose (5mg) of tadalafil is also applied for the treatment of male lower urinary tract symptoms (LUTS) associated with benign prostate hyperplasia (BPH). PDE5 inhibitors induce relaxation of smooth muscle cells in urethra, prostate, bladder neck and blood vessels. The aim of this study is to investigate the efficacy of tadalafil for vessels endothelial function, besides male LUTS symptoms in patients with BPH.
METHODS: The Institutional Review Board (IRB) had approved this clinical study, and informed consents have been obtained from 70 BPH patients.
(1) The male LUTS parameters such as international prostate symptom score (IPSS), overactive bladder symptom score (OABSS), residual urine (RU) were compared before and 1month, 3 months, 6 months, 12months after daily 5mg tadalafil treatment. (2) In addition, erectile function and vessels endothelial function were evaluated by sexual health inventory for men (SHIM) score, brachialankle pulse wave velocity (baPWV) and ankle brachial index (ABI) before and 3 months, 6 months, 12months after tadalafil treatment. RESULTS: The mean age of 70 patients were 65.7+/-11.6 years old. The prostate size was 30.2+/-22.7 ml.
(1) All male LUTS parameters including total IPSS, OABSS and RU were significantly improved 1 to 12 months after tadalafil administration. (2) Furthermore, SHIM score significantly improved after 3 months.
baPWV is a measure of arterial stiffness and a marker of vascular damages. Generally, higher baPWV means that the vessels are less elasticity, and baPWV data increase according to aging. The results of baPWV significantly improved from 3 to 6 months (p<0.01) and the same levels at 12 months compared with baseline ( Figure) . ABI is an indicator of arterial sclerosis and arterial sclerosis is diagnosed when ABI is less than 0.9. In this study, ABI was not significantly changed by tadalafil. CONCLUSIONS: Tadalafil is effective not only for male LUTS but also ED. Furthermore, tadalafil improves baPWV data, which means higher vessels elasticity has been obtained. The major new finding of this study is that tadalafil had a potency to improve vessels endothelial dysfunction in patients with BPH.
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